Takeda Pharmaceutical Company Limited (TAK)
| Market Cap | 53.07B |
| Revenue (ttm) | 30.50B |
| Net Income (ttm) | 410.02M |
| Shares Out | 1.68B |
| EPS (ttm) | 0.81 |
| PE Ratio | 20.59 |
| Forward PE | 8.76 |
| Dividend | $1.64 |
| Dividend Yield | 9.78% |
| Trading Day | February 26 |
| Last Price | $16.71 |
| Previous Close | $16.75 |
| Change ($) | -0.04 |
| Change (%) | -0.24% |
| Day's Open | 16.81 |
| Day's Range | 16.57 - 16.96 |
| Day's Volume | 4,779,218 |
| 52-Week Range | 11.82 - 19.55 |
Glenview Capital Management recently disclosed its portfolio updates for the fourth quarter of 2020, which ended on Dec. 31.
Takeda Pharmaceutical Co Ltd (NYSE: TAK) will sell its four non-core type-2 diabetes products (Nesina, Liovel, Inisync, and Zafatek) in Japan to Teijin Pharma Limited, ¥133 billion (roughly $1...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to transfer the assets, marketing ...
MORENO VALLEY, Calif.--(BUSINESS WIRE)--BioLife Plasma Services announces expansion of plasma donation centers into California.
Takeda Pharmaceutical Co Ltd (NYSE: TAK) said that the first patient had been dosed with Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine candidate (dubbed as TAK-019) in a Japanese clinical tria...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced today that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of No...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...
ZURICH--(BUSINESS WIRE)-- #EURORDISAwards2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) Takeda has been announced the winner of the EURORDIS 2021 Award for Patient ...
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has announced data from SOLSTICE Phase 3 trial, evaluating maribavir (TAK-620) in hematopoietic cell transplant and solid organ transplant recipients w...
OSAKA, Japan--(BUSINESS WIRE)--Takeda's Maribavir Phase 3 Clinical Trial Met Primary Endpoint
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has applied to the Japanese regulatory authority seeking approval for Darvadstrocel (Cx601) to treat complex perianal fistulas in adult patients with n...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has submitted an application to the Japanese Ministry of Health, Lab...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the third quarter of fiscal year 2020 (period ended ...
OSAKA, Japan--(BUSINESS WIRE)--Data at EAHAD 2021 Highlight Value of Takeda's Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has completed the previously announced sale of TachoSil® Fibrin Seal...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select pro...
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data from the Phase 1/2 trial of mobocertinib (TAK-78...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it achieved carbon neutrality in its value chain for its fiscal year 20...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) has earned an industry-leading position within the 2021 Access to Medicin...
A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it is one of only 16 companies to achieve global Top...
EXTON, Pa., Jan. 20, 2021 /PRNewswire/ -- Two 2020 European Medical Agency (EMA) approvals, Takeda's Entyvio SC and Celltrion Healthcare's infliximab biosimilar, Remsima SC, have captured nota...
According to the Aggregated Portfolio of Gurus, a Premium feature of GuruFocus, the Hennessy Japan Fund (Trades, Portfolio), the T. Rowe Price Japan Fund (Trades, Portfolio) and the Matthews J...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) provided an update on the progress of its continued transformation and gr...
Pharmaceutical stocks can be a great investment in a unique niche of the market. The stocks on this list will be strong for a decade plus.
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) will present virtually at the 39th Annual J.P. Morgan Healthcare Confer...
Screening the market for securities whose market capitalization surpasses $2 billion and whose price-book ratios are trading below 1.5 could yield a higher likelihood of unearthing value oppor...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select pre...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of non-core pres...
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the su...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepte...
Japan's Takeda Pharmaceutical Co said on Wednesday its drug pipeline is poised to drive annual sales up by more than 50%, to 5 trillion yen ($48.01 billion) in the next decade.
OSAKA, Japan--(BUSINESS WIRE)--As part of its Wave 1 Pipeline Market Opportunity Call, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) provided an update on its pipeline p...
SHANGHAI & OSAKA, Japan--(BUSINESS WIRE)--Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda today presented five hematology poster presentations and four abstracts at the 62nd American Society of Hematology (ASH) Annual Meeting.
CAMBRIDGE, Mass. and OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the U.S. availability of myPKFiT® for ADYNOVATE® [Antih...
INCHEON, South Korea--(BUSINESS WIRE)-- #Acquisition--Celltrion completed an acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited.
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select pro...
THOUSAND OAKS, Calif., Nov. 30, 2020 /PRNewswire/ -- Three members of the COVID R&D Alliance - Amgen Inc. (NASDAQ: AMGN), Takeda Pharmaceutical Co. Ltd. (NYSE: TAK), and UCB (Euronext BR: UCB)...
PARIS--(BUSINESS WIRE)--Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells (Tre...
Takeda Pharma's Venkayya on Global Race for Covid Vaccines
Nov.22 -- Rajeev Venkayya, president of the global vaccine business unit of Japan's Takeda Pharmaceutical Co., discusses the latest developments in the global race for Covid-19 vaccines. The c...
The numbers are close, but two players stand out at the moment.
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced it will present nine company-sponsored abstracts at the 62nd Americ...
Japan's Takeda Pharmaceutical Co is looking at making vaccines a core business after completing asset sales to lower debt following its takeover of Shire Plc, Chief Executive Christophe Weber ...
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present 22 company-sponsored abstracts at th...
Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q2 2021 Results - Earnings Call Transcript
SAN DIEGO, Oct. 29, 2020 /PRNewswire/ -- Seqster PDM Inc. ("Seqster") the award winning healthcare technology company and Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ("Takeda")...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first half of fiscal year 2020 (period ended Septe...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), announced today that it will import and distribute 50 million doses of Moderna's COVID-19 vaccine cand...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna partners with Takeda and the government of Japan to supply 50 million doses of mRNA vaccine against COVID-19 (mRNA-1273) to Japan.
About TAK
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | Founded 1781 |
| CEO Christophe Weber | Employees 47,495 |
| Stock Exchange NYSE | Ticker Symbol TAK |
Financial Performance
In 2019, TAK's revenue was 3.29 trillion, an increase of 56.93% compared to the previous year's 2.10 trillion. Earnings were 44.24 billion, a decrease of -67.28%.
Analyst Forecasts
According to 3 analysts, the average rating for TAK stock is "Buy." The 12-month stock price forecast is 22.74, which is an increase of 36.09% from the latest price.